



NMS Labs

CONFIDENTIAL

200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

Demo Report

Report Issued 11/21/2022 07:44
Last Report Issued 11/04/2022 14:38

88888
Clinical Example Report
Attn: Example Reports
200 Welsh Road
Horsham, PA 19044

Patient Name NA
Patient ID 3428SP-POS
Chain 22002354
DOB Not Given
Sex Not Given
Workorder 22002354
Received 11/03/2022

Lab ID 22002354-001
Matrix Serum or Plasma
Patient Name NA
Patient ID 3428SP-POS
Container Type Black Cap Glass Container

Collect Dt/Tm Not Given
Source Not Given

Approx Vol/Weight Not Given

Receipt Notes None Entered

Table with 5 columns: Analysis and Comments, Result, Units, Reporting Limit, Notes. Contains data for PFHxA, PFBS, PFHpA, and ADONA.

Results for sample 22002354-001 are continued on next page



NMS Labs

CONFIDENTIAL

200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

Lab ID 22002354-001
Matrix Serum or Plasma
Patient Name NA
Patient ID 3428SP-POS

Collect Dt/Tm Not Given
Source Not Given

Table with 5 columns: Analysis and Comments, Result, Units, Reporting Limit, Notes. Contains data for various PFOA and PFOS isomers with their respective concentrations and reporting limits.

Results for sample 22002354-001 are continued on next page



NMS Labs

CONFIDENTIAL

200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

Lab ID 22002354-001
Matrix Serum or Plasma
Patient Name NA
Patient ID 3428SP-POS

Collect Dt/Tm Not Given
Source Not Given

Table with 5 columns: Analysis and Comments, Result, Units, Reporting Limit, Notes. Rows include Linear PFOS Isomer (60 ng/mL), Total PFOS Isomers (115 ng/mL), PFHpS (65 ng/mL), PFUnDA (70 ng/mL), MeFOSAA (75 ng/mL), and PFDoDA (80 ng/mL). Each row includes general population reference ranges and specific comments.

Results for sample 22002354-001 are continued on next page



**NMS Labs**

**CONFIDENTIAL**

200 Welsh Road, Horsham, PA 19044-2208  
Phone: (215) 657-4900 Fax: (215) 657-2972  
e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

**Lab ID** 22002354-001  
**Matrix** Serum or Plasma  
**Patient Name** NA  
**Patient ID** 3428SP-POS

**Collect Dt/Tm** Not Given  
**Source** Not Given

Analysis and Comments	Result	Units	Reporting Limit	Notes
PFOSA Synonym(s): Perfluorooctane Sulfonamide General U.S. population from CDC-NHANES (2011-2012) (n=1904) is typically below 0.10 ng/mL (95th percentile)	85	ng/mL	0.10	ELEVATED
NASEM Summation Value The National Academies of Science, Engineering, and Medicine (NASEM) recommends the following clinical guidance related to an additive sum value for MeFOSAA, PFHxS, PFOA (linear and branched isomers), PFDA, PFUnDA, PFOS (linear and branched isomers), and PFNA in serum or plasma: -Adverse health effects related to PFAS exposure are not expected at less than 2 ng/mL. -There is a potential for adverse effects, especially in sensitive populations, between 2 and 20 ng/mL. -There is an increased risk of adverse effects at greater than 20 ng/mL.	460	ng/mL		ELEVATED

This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.